The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal Fluid
Open accessAbstract
IMPORTANCE: Parkinson disease (PD) is a highly prevalent and incurable neurodegenerative disease associated with the accumulation of misfolded α-synuclein (αSyn) aggregates. An important problem in this disease is the lack of a sensitive, specific, and noninvasive biochemical diagnosis to help in clinical evaluation, monitoring of disease progression, and early differential diagnosis from related neurodegenerative diseases. OBJECTIVE: To develop a novel assay with high sensitivity and specificity to detect small quantities of αSyn aggregates circulating in cerebrospinal fluid (CSF) of patients affected by PD and related synucleinopathies. DESIGN, SETTING, AND PARTICIPANTS: The strategy evaluated in this proof-of-concept study uses the protein misfolding cyclic amplification (PMCA) technology that detects minute amounts of misfolded oligomers by taking advantage of their ability to nucleate further aggregation, enabling a very high amplification of the signal. The technology was first adapted with synthetic αSyn oligomers prepared in vitro and used to screen in 2 blinded cohorts of CSF samples from German and Japanese patients with PD (n = 76) and individuals serving as controls affected by other neurologic disorders (n = 65), neurodegenerative diseases (n = 18), and Alzheimer disease (n = 14). The kinetics of αSyn aggregation were measured by αSyn-PMCA in the presence of CSF samples from the participants to detect αSyn oligomeric seeds present in this biological fluid. The assays were conducted from November 15, 2013, to August 28, 2015. MAIN OUTCOMES AND MEASURES: Kinetic parameters correlated with disease severity at the time of sample collection, measured by the Hoehn and Yahr scale, with the lowest grade indicating unilateral involvement with minimal or no functional impairment, and the highest grade defining patients with complete confinement to wheelchair or bed. RESULTS: Studies with synthetic αSyn aggregates showed that αSyn-PMCA enabled to detect as little as 0.1 pg/mL of αSyn oligomers. The αSyn-PMCA signal was directly proportional to the amount of αSyn oligomers added to the reaction. A blinded study of CSF samples correctly identified patients affected by PD with an overall sensitivity of 88.5% (95% CI, 79.2%-94.6%) and specificity of 96.9% (95% CI, 89.3%-99.6%). The αSyn-PMCA results for different patients correlated with the severity of the clinical symptoms of PD (Japanese cohort: rs = -0.54, P = .006; German cohort: rs = -0.36, P = .02). CONCLUSIONS AND RELEVANCE: The findings suggest that detection of αSyn oligomers by αSyn-PMCA in the CSF of patients affected by PD may offer a good opportunity for a sensitive and specific biochemical diagnosis of the disease. Further studies are needed to investigate the usefulness of αSyn-PMCA to monitor disease progression and for preclinical identification of patients who may develop PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Tsigelny, I. F., Crews, L., Desplats, P., Shaked, G. M., Sharikov, Y., Mizuno, H., Spencer, B., Rockenstein, E., Trejo, M., Platoshyn, O., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003135 · Cited by 281
RetractedAccumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo
Rockenstein, E., Nuber, S., Overk, C. R., Ubhi, K., Mante, M., Patrick, C., Adame, A., Trejo-Morales, M., Gerez, J., Picotti, P., et al. (2014) · Brain · doi:10.1093/brain/awu057 · Cited by 238
RetractedParkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720
Goetz, C. G., Poewe, W., Rascol, O., Sampaio, C., Stebbins, G. T., Counsell, C., Giladi, N., Holloway, R. G., Moore, C. G., Wenning, G. K., et al. (2004) · Movement Disorders · doi:10.1002/mds.20213 · Cited by 2,347
Levine, H. (1993) · Protein Science · doi:10.1002/pro.5560020312 · Cited by 2,264
(1998) · Europe PMC (PubMed Central) · Cited by 1,594
Unfolding the role of protein misfolding in neurodegenerative diseases
Soto, C. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1007 · Cited by 1,506
Self-citationSensitive detection of pathological prion protein by cyclic amplification of protein misfolding
Saborio, G. P., Permanne, B., & Soto, C. (2001) · Nature · doi:10.1038/35081095 · Cited by 1,310
Self-citationParkinsonism: Onset, progression, and mortality
Hoehn, M., & Yahr, M. (2011) · Neurology · doi:10.1212/01.wnl.0000405146.06300.91 · Cited by 1,061
Parkinson's Disease and Parkinsonism: Neuropathology
Dickson, D. W. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009258 · Cited by 847
Hamilton, R. L. (2000) · Brain Pathology · doi:10.1111/j.1750-3639.2000.tb00269.x · Cited by 754
α-Synuclein Fibrillogenesis Is Nucleation-dependent
Wood, S. J., Wypych, J., Steavenson, S., Louis, J.-C., Citron, M., & Biere, A. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.28.19509 · Cited by 720
El‐Agnaf, O. M. A., Salem, S. A., Paleologou, K. E., Curran, M. D., Gibson, M. J., Court, J. A., Schlossmacher, M. G., & Allsop, D. (2006) · The FASEB Journal · doi:10.1096/fj.03-1449com · Cited by 715
Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion
Atarashi, R., Satoh, K., Sano, K., Fuse, T., Yamaguchi, N., Ishibashi, D., Matsubara, T., Nakagaki, T., Yamanaka, H., Shirabe, S., et al. (2011) · Nature Medicine · doi:10.1038/nm.2294 · Cited by 656
Mollenhauer, B., Locascio, J. J., Schulz-Schaeffer, W., Sixel-Döring, F., Trenkwalder, C., & Schlossmacher, M. G. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70014-x · Cited by 622
Self-citationClinton, L. K., Blurton-Jones, M., Myczek, K., Trojanowski, J. Q., & LaFerla, F. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0490-10.2010 · Cited by 576
Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease
Tokuda, T., Qureshi, M. M., Ardah, M. T., Varghese, S., Shehab, S. A. S., Kasai, T., Ishigami, N., Tamaoka, A., Nakagawa, M., & El-Agnaf, O. M. A. (2010) · Neurology · doi:10.1212/wnl.0b013e3181fd613b · Cited by 527
Self-citationLow clinical diagnostic accuracy of early vs advanced Parkinson disease: Clinicopathologic study
Adler, C. H., Beach, T. G., Hentz, J. G., Shill, H. A., Caviness, J. N., Driver-Dunckley, E., Sabbagh, M. N., Sue, L. I., Jacobson, S. A., Belden, C. M., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000641 · Cited by 503
Biomarkers of Parkinson’s disease: Present and future
Miller, D. B., & O’Callaghan, J. P. (2015) · Metabolism · doi:10.1016/j.metabol.2014.10.030 · Cited by 358
Saá, P., Castilla, J., & Soto, C. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603964200 · Cited by 328
Self-citationSimplified ultrasensitive prion detection by recombinant PrP conversion with shaking
Atarashi, R., Wilham, J. M., Christensen, L., Hughson, A. G., Moore, R. A., Johnson, L. M., Onwubiko, H. A., Priola, S. A., & Caughey, B. (2008) · Nature Methods · doi:10.1038/nmeth0308-211 · Cited by 314
Castilla, J., Saá, P., & Soto, C. (2005) · Nature Medicine · doi:10.1038/nm1286 · Cited by 314
Self-citationα‐Synuclein oligomers and clinical implications for Parkinson disease
Kalia, L. V., Kalia, S. K., McLean, P. J., Lozano, A. M., & Lang, A. E. (2013) · Annals of Neurology · doi:10.1002/ana.23746 · Cited by 292
Lewy body-related ?-synucleinopathy in the aged human brain
Jellinger, K. A. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0138-7 · Cited by 256
Presymptomatic Detection of Prions in Blood
Saá, P., Castilla, J., & Soto, C. (2006) · Science · doi:10.1126/science.1129051 · Cited by 231
Self-citationWalker, L., McAleese, K. E., Thomas, A. J., Johnson, M., Martin-Ruiz, C., Parker, C., Colloby, S. J., Jellinger, K., & Attems, J. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1406-3 · Cited by 225
Detection of CWD Prions in Urine and Saliva of Deer by Transgenic Mouse Bioassay
Haley, N. J., Seelig, D. M., Zabel, M. D., Telling, G. C., & Hoover, E. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004848 · Cited by 224
Mandal, P. K., Pettegrew, J. W., Masliah, E., Hamilton, R. L., & Mandal, R. (2006) · Neurochemical Research · doi:10.1007/s11064-006-9140-9 · Cited by 219
Morales, R., Moreno-Gonzalez, I., & Soto, C. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003537 · Cited by 218
Self-citationSeeking a Mechanism for the Toxicity of Oligomeric α-Synuclein
Roberts, H., & Brown, D. (2015) · Biomolecules · doi:10.3390/biom5020282 · Cited by 212
Prions in the Urine of Patients with Variant Creutzfeldt–Jakob Disease
Moda, F., Gambetti, P., Notari, S., Concha-Marambio, L., Catania, M., Park, K.-W., Maderna, E., Suardi, S., Haïk, S., Brandel, J.-P., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1404401 · Cited by 211
Self-citationCross‐seeding effects of amyloid β‐protein and α‐synuclein
Ono, K., Takahashi, R., Ikeda, T., & Yamada, M. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07847.x · Cited by 210
Hansson, O., Hall, S., Öhrfelt, A., Zetterberg, H., Blennow, K., Minthon, L., Nägga, K., Londos, E., Varghese, S., Majbour, N. K., et al. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt255 · Cited by 205
Detection of Misfolded Aβ Oligomers for Sensitive Biochemical Diagnosis of Alzheimer’s Disease
Salvadores, N., Shahnawaz, M., Scarpini, E., Tagliavini, F., & Soto, C. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.031 · Cited by 197
Self-citationCyclic amplification of protein misfolding: application to prion-related disorders and beyond
Soto, C., Saborio, G. P., & Anderes, L. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(02)02195-1 · Cited by 188
Self-citationLee, V. M.-Y., Giasson, B. I., & Trojanowski, J. Q. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.01.007 · Cited by 187
Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort
Mollenhauer, B., Trautmann, E., Sixel-Döring, F., Wicke, T., Ebentheuer, J., Schaumburg, M., Lang, E., Focke, N. K., Kumar, K. R., Lohmann, K., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a6cbd5 · Cited by 182
Self-citationCerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases
Lleó, A., Cavedo, E., Parnetti, L., Vanderstichele, H., Herukka, S. K., Andreasen, N., Ghidoni, R., Lewczuk, P., Jeromin, A., Winblad, B., et al. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.232 · Cited by 159
Self-citationTotal CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects
Mollenhauer, B., Trautmann, E., Taylor, P., Manninger, P., Sixel‐Döring, F., Ebentheuer, J., Trenkwalder, C., & Schlossmacher, M. G. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.11.004 · Cited by 144
Self-citationDetection of infectious prions in urine
Gonzalez-Romero, D., Barria, M. A., Leon, P., Morales, R., & Soto, C. A. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.08.003 · Cited by 135
Self-citationCompta, Y., Valente, T., Saura, J., Segura, B., Iranzo, Á., Serradell, M., Junqué, C., Tolosa, E. S., Valldeoriola, F., Muñoz, E., et al. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7560-z · Cited by 119
Aggregation and neurotoxicity of recombinant α-synuclein aggregates initiated by dimerization
Roostaee, A., Beaudoin, S., Staskevicius, A., & Roucou, X. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-5 · Cited by 81
Amplification of Tau Fibrils from Minute Quantities of Seeds
Meyer, V., Dinkel, P. D., Hager, E. R., & Margittai, M. (2014) · Biochemistry · doi:10.1021/bi501050g · Cited by 76
Bhak, G., Lee, J., Hahn, J., & Paik, S. R. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004177 · Cited by 62
Murayama, Y., Yoshioka, M., Masujin, K., OKADA, H. M., Iwamaru, Y., Imamura, M., Matsuura, Y., Fukuda, S., Onoe, S., Yokoyama, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013152 · Cited by 56
Accuracy of Parkinson disease diagnosis unchanged in 2 decades
Rajput, A. H., & Rajput, A. H. (2014) · Neurology · doi:10.1212/wnl.0000000000000653 · Cited by 51
A novel method for preclinical detection of PrPSc in blood
Rubenstein, R., Chang, B., Gray, P., Piltch, M. S., Bulgin, M. S., Sorensen-Melson, S., & Miller, M. W. (2010) · Journal of General Virology · doi:10.1099/vir.0.020164-0 · Cited by 51
Protein misfolding cyclic amplification (PMCA): Current status and future directions
Saá, P., & Červen̆áková, L. (2014) · Virus Research · doi:10.1016/j.virusres.2014.11.007 · Cited by 37
Parkinson’s Disease and Alpha-Synucleinopathies: from Arising Pathways to Therapeutic Challenge
Miraglia, F., Betti, L., Palego, L., & Giannaccini, G. (2015) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/1871524915666150421114338 · Cited by 33
Murayama, Y., Masujin, K., Imamura, M., Ono, F., Shibata, H., Tobiume, M., Yamamura, T., Shimozaki, N., Terao, K., Yamakawa, Y., et al. (2014) · Journal of General Virology · doi:10.1099/vir.0.066225-0 · Cited by 21
Cited by
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13859 · Cited by 2,803
Challenges in the diagnosis of Parkinson's disease
Tolosa, E., Garrido, A., Scholz, S. W., & Poewe, W. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00030-2 · Cited by 1,874
Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases
Soto, C., & Pritzkow, S. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0235-9 · Cited by 1,180
Self-citationDiscriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy
Shahnawaz, M., Mukherjee, A., Pritzkow, S., Mendez, N., Rabadia, P., Liu, X., Hu, B., Schmeichel, A., Singer, W., Wu, G., et al. (2020) · Nature · doi:10.1038/s41586-020-1984-7 · Cited by 820
Self-citationSiderowf, A., Concha-Marambio, L., Lafontant, D.-E., Farris, C. M., Ma, Y., Urenia, P. A., Nguyen, H., Alcalay, R. N., Chahine, L. M., Foroud, T., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00109-6 · Cited by 719
Self-citation
Metadata
- Authors
- Shahnawaz, M., Tokuda, T., Waragai, M., Mendez, N., Ishii, R., Trenkwalder, C., Mollenhauer, B., & Soto, C.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2017-02-01
- Volume
- 74
- Issue
- 2
- Pages
- 163
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W2560746397
- Cited by
- 489
- References
- 52
- FWCI
- 20.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.